Skip to main content
Fig. 2 | Malaria Journal

Fig. 2

From: Plasmodium falciparum pre-erythrocytic stage vaccine development

Fig. 2

a Schematic representation of P. falciparum’s CSP1 (NF54 strain), showing signal peptide (orange), region I (blue), the central repeat regions (yellow, green and red) and region II (blue) with GPI anchor (pink). b Schematic representation of RTS,S vaccine, showing the central repeat regions (orange, grey) and PfCSP1 region II (blue) and hepatitis B virus (purple) surface antigen (S). c Ribbon and surface representation of PfCSP1 region II. (PDB: 3VDK) [177]. d Schematic representation of ChAd63/MVA ME-TRAP vaccine candidate. Left-hand side, above, pSG2 plasmid used to express the ME-TRAP vaccine candidate in either ChAd63 or MVA viruses involving kanamycine resistant (KanR) (in blue) cytomegalovirus, with intron A (pCMV IntA) (in red), bovine growth hormone with terminator polyA (BGH poly-A) (in orange) and Escherichia coli B-galactosidase genes (in yellow). Right-hand side, above, PfTRAP TRS domain in ribbon and surface representation (PDB 2BBX) [178]. Bottom, PfTRAP Von Willebrand factor A domain (vWA), in ribbon and surface, showing the MIDAS domain residues (blue). e pSG2 plasmid used to express the CS vaccine candidate in either ChAd63 or MVA viruses with the same vector as represented in E

Back to article page